China, AstraZeneca

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, ...
Guidance: For fiscal year 2024, AstraZeneca forecasts total revenue and core EPS to increase by a high-teens percentage, ...
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...
Trump has threatened to slap a tariff of up to 60% on all goods imported to the U.S. from China. But Soriot called his ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...